| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/03/2003 | CA2450828A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 01/03/2003 | CA2450758A1 Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450555A1 (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450446A1 Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| 01/03/2003 | CA2450001A1 Stable pharmaceutical compositions containing pravastatin |
| 01/03/2003 | CA2449998A1 Stable controlled release pharmaceutical compositions containing pravastatin |
| 01/02/2003 | US20030005470 Animal model for use in the diagnosis and treatment of tumors and bone matastasis |
| 01/02/2003 | US20030004499 Method and apparatus for the photomodulation of living cells |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004327 Cerebellum and embryo specific protein |
| 01/02/2003 | US20030004317 Nucleic acids encoding anti-human alphanubeta3 and alphanubeta5 antibodies |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004209 Anti-angiogenic compositions and methods of use |
| 01/02/2003 | US20030004203 Benzimidazole derivatives as modulators of IgE |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004191 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor |
| 01/02/2003 | US20030004187 Method for preventing dyskinesias |
| 01/02/2003 | US20030004178 Synergistic mixture |
| 01/02/2003 | US20030004177 Abuse-resistant opioid dosage form |
| 01/02/2003 | US20030004176 Mixture of analgesic and addition reducting compound of a gamma-aminobutyric acid |
| 01/02/2003 | US20030004175 Viricides |
| 01/02/2003 | US20030004170 Mixture of adrenergic blocking agent and phosphodiesterase inhibitor |
| 01/02/2003 | US20030004168 Mixture of hypotensive agent and calcium channel blockers; cardiovascular disorders |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004162 Antidiabetic agents; dietetics |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004157 Neurokinin antagosnist receptor |
| 01/02/2003 | US20030004152 Method of treating sexual disturbances |
| 01/02/2003 | US20030004145 Endometriosis, memopause therapy; controlling dosage cycles |
| 01/02/2003 | US20030004143 In situ supplying; anticancer, antitumor agents |
| 01/02/2003 | US20030004142 In situ supplying; anticancer, antitumor agents |
| 01/02/2003 | US20030004139 Antidiabetic agents |
| 01/02/2003 | US20030004134 Concurrent administering with chemoreceptors; central nervous system disorders |
| 01/02/2003 | US20030004132 Binding to galectins; therapy for autoimmune disease |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004128 Formulatios of adenosine a1 agonists |
| 01/02/2003 | US20030004127 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004126 Formulations of adenosine A1 agonists |
| 01/02/2003 | US20030004119 Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 01/02/2003 | US20030004118 Antibiotic/benzoyl peroxide dispenser |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030004100 Method of modifying the release profile of sustained release compositions |
| 01/02/2003 | US20030004093 Method for identifying compounds for inhibition of neoplastic lesions |
| 01/02/2003 | US20030004091 Medicinal combination useful for in vivo exogenic transfection and expression |
| 01/02/2003 | US20030003576 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 01/02/2003 | US20030003541 Nucleotide sequences coding peptide for use in the treatment of skin, brain and eye disorders |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003513 Compounds and methods for the inhibition of protein-protein interactions |
| 01/02/2003 | US20030003470 Kit for use in the diagnosis of hypertension; obtain sample, determine pattern of alleles, detect preferential gene expression, preferential gene expression indicates hypertension |
| 01/02/2003 | US20030003447 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/02/2003 | US20030003444 R9Detection of preferential polypeptide in sample; obtain sample of polypeptide, incubate with bacteriophage, monitor adjustment in activity, adjustment in activity |
| 01/02/2003 | US20030003163 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 01/02/2003 | US20030003162 Administering a vitamin (ascorbic acid), an amino acid (arginine) and a trace element (magnesium) for treatment of high blood pressure, asthma, glaucoma and tinnitus |
| 01/02/2003 | US20030003151 Chemical delivery device |
| 01/02/2003 | US20030003138 Articles with spores exhibiting antagonistic properties against pathogens and/or spores forming micro-organisms |
| 01/02/2003 | US20030003128 A prosthetic for dental implants comprising a polymeric base material(hydrogel) incorporating at least one active drug and base material releases active drug in a controlled manner when the prosthtic has been implanted in living organism |
| 01/02/2003 | US20030003107 Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof |
| 01/02/2003 | US20030003102 Morpholino imaging and therapy |
| 01/02/2003 | US20030003101 Treatment and diagnosis of prostate cancer |
| 01/02/2003 | US20030003099 Immunosuppressive combination and its use in the treatment or prophylaxis of insulin-producing cell graft rejection |
| 01/02/2003 | US20030003097 Recombinant antibodies coexpressed with GnTIII |
| 01/02/2003 | US20030003094 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 01/02/2003 | US20030003092 Administering an immunotherapeautic agent in conjunction with a tumour growth restricting agent, in amounts effective to eradicate any advanced or large tumours present |
| 01/02/2003 | US20030003047 Tumor radiotherapy |
| 01/02/2003 | US20030000518 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/02/2003 | EP1271153A2 Collapsin response mediator protein-1 as tumor metastasis marker |
| 01/02/2003 | EP1270594A1 Antibodies to peptide from a soluble fragment of acetylcholinesterase |
| 01/02/2003 | EP1270586A2 Composition for the cell-specific transfer of active substances |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270002A2 Pharmaceutical compositions for preventing problem behaviour of companion animals |
| 01/02/2003 | EP1270000A2 Benzoic acid substituted benzopyrans for the treatment of atherosclerosis |
| 01/02/2003 | EP1269990A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269989A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269988A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269984A1 Cosmetic and/or dermatological andor pharmaceutical composition for topical application containing at least one compound inhibiting 3-beta-HSD enzyme |
| 01/02/2003 | EP1269860A1 Pharmaceutical composition |
| 01/02/2003 | EP1269198A2 Identification of mast/basophil activation inhibitors |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1269183A1 Assay for agents that induce chemokinesis |
| 01/02/2003 | EP1269180A1 Methods for screening and identifying pathogen virulence factors |
| 01/02/2003 | EP1268854A1 High specificity marker detection |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268817A1 Human pyruvate dehydrogenese phosphatase |
| 01/02/2003 | EP1268816A2 Calcium-binding regulatory subunit |
| 01/02/2003 | EP1268812A2 Vectors for gene therapy |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268787A2 Human tap-like protein (transporter associated in antigen processing/presentation) |
| 01/02/2003 | EP1268786A2 Use of p-selectin glycoprotein ligand-1 (psgl-1) and fragments thereof for the inhibition of thrombosis |
| 01/02/2003 | EP1268785A2 Gtp-binding protein gamma-12 subunit |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268774A2 Identification of essential genes in prokaryotes |
| 01/02/2003 | EP1268772A2 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 01/02/2003 | EP1268756A2 Methods and compositions for modulating integrin-mediated cell-cell interactions |